MMJ International Holdings, the premier medical cannabis research company, has received DEA and Health Canada approval and is shipping highly concentrated THC and CBD from Canada to the United States. MMJ International Holdings is developing an oral drug product from natural whole plant extract derivatives from the marijuana plant containing THC and CBD. MMJ will be utilizing its new product for a FDA approved clinical trials in multiple sclerosis (MS) and Huntington's disease (HD). The US Drug Enforcement Agency's approved MMJ to ship the compounds for its clinical trials.
